Inversago Pharma
Inversago Pharma, based in Montreal, Canada, specializes in developing therapies targeting peripheral CB1 receptors, focusing on metabolic and fibrotic diseases. The company's lead program, INV-202, is in Phase 2 studies for diabetic kidney disease and obesity.
Company Overview
Inversago Pharma, based in Montreal, Canada, focuses on developing therapies targeting peripheral cannabinoid-1 (CB1) receptors. Founded on the goal of addressing metabolic and fibrotic diseases, the company has positioned itself at the forefront of innovative pharmaceutical solutions for serious health conditions.
Lead Program: INV-202
The lead program of Inversago Pharma, INV-202, is being evaluated in Phase 2 studies for its efficacy in treating diabetic kidney disease and obesity. In a Phase 1b trial, INV-202 demonstrated potential in promoting weight loss. The ongoing studies aim to further verify and expand on these promising results, potentially providing a new therapeutic option for patients with these conditions.
Pipeline: INV-347 and INV-101
Inversago Pharma's pipeline includes two notable candidates: INV-347 and INV-101. INV-347 targets metabolic disorders and is currently in a Phase 1 trial. On the other hand, INV-101 is being developed for the treatment of idiopathic pulmonary fibrosis, a serious condition characterized by progressive lung scarring. These initiatives showcase the company's commitment to addressing both metabolic and fibrotic diseases.
Acquisition by Novo Nordisk
In 2023, Novo Nordisk, a global leader in diabetes care, acquired Inversago Pharma. This acquisition underscores the innovative potential of Inversago's therapeutic programs and aligns with Novo Nordisk's strategic focus on expanding its metabolic disease treatment portfolio. The integration is expected to leverage Novo Nordisk’s extensive resources to advance Inversago’s current and future projects.
Therapeutic Focus
Inversago Pharma specializes in the development of therapies targeting peripheral CB1 receptors. This unique approach is aimed at treating a range of metabolic and fibrotic diseases, areas of significant unmet medical need. The company's research and development strategy reflects a strong commitment to bringing novel and effective treatments to market, particularly for conditions that currently lack sufficient therapeutic options.